How to relax your pelvic floor muscles
Are you paying attention to your pelvic floor health?
The pelvic floor is a group of muscles and nerves that form a "supportive hammock" from the back, through the tailbone, lower abdominal area and hips, gynecologist and urologist Sonia Bahlani, M.D., tells USA TODAY. Together, this dictates urinary and fecal patterns, sexual function and even how you sit.
"People never think of the pelvic floor as this powerhouse of the body, but it truly is," Dr. Bahlani says.
A common misconception about the pelvic floor, Dr. Bahlani highlights, is thinking that the opposite of a tight pelvic floor is a weak pelvic floor.
"People think of a tight pelvic floor as a strong pelvic floor. But a tight pelvic floor, in fact, is a weak pelvic floor," she says. They're two sides of the same coin: Both cause similar issues, but the way they're treated usually differs.
Another misconception: that pelvic floor issues are only a concern for people who have vaginas. They actually impact everyone, regardless of their anatomy, Dr. Bahlani notes.
Here's what health experts want you to know about identifying a tight pelvic floor, and how best to fix one.
'Take care of your pelvic floor' Brittany Mahomes speaks out after injury
Roughly a third of women and 16% of men will experience some kind of pelvic floor disorder in their lifetime, statistics have shown.
A tight pelvic floor is what happens when the muscles are in a constant state of contraction, according to the Cleveland Clinic. This leads to issues including urinary or fecal incontinence, painful sex or pelvic organ prolapse, which is when "you can actually feel the uterus come through the vagina," Dr. Bahlani says.
If you're struggling with those issues, a doctor may test your pelvic floor strength with a biofeedback machine, Dr. Bahlani says. "They'll say, 'contract your pelvic floor muscles, so act like you're pushing stool out or act like you're peeing,'" she says. "And they can measure how strong the pelvic floor is."
You've likely heard of Kegels: the exercise where you contract muscles as if you're trying to avoid passing gas, pretending to tighten the vagina around a tampon or stopping your urine stream, according to Harvard Health.
It's the best-known way to strengthen the pelvic floor, but it may not actually be the best one for you.
Many women experience pain with sex. Is pelvic floor therapy the answer not enough people are talking about?
"Kegels only work for a subset of patients whose weak pelvic floor is due to laxity of the muscles, as opposed to tightness of the muscles," Dr. Bahlani says. She only advises about 20% of her patients to use Kegels alone; others are better suited with physical therapy, yoga poses, bird dog and core strengthening exercises.
In other words, kegels could be helpful if your pelvic floor is weak, but tight pelvic floors are better treated through tactics such as yoga, meditation and other relaxing techniques.
This article originally appeared on USA TODAY: How to relax your pelvic floor muscles
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
17 hours ago
- USA Today
Orangetheory opening new studios in 6 states this year. See where.
Orangetheory continues to add locations to its growing fitness studio chain. The one-hour workout gym, which describes itself as the "multivitamin of workouts," operates nearly 1,300 studios and sees growth opportunities in mid-sized cities and suburban markets, the company said in an email to USA TODAY. Orangetheory also pointed to growth opportunities in larger markets including Dallas, Los Angeles and Seattle. Orangetheory merged with Self Esteem Brands in 2024 and is now a part of the Purpose Brands portfolio, which includes Anytime Fitness, Basecamp Fitness and SUMHIIT Fitness along with other fitness and wellness brands. Here's where Orangetheory Fitness is set to open new locations. Need a break? Play the USA TODAY Daily Crossword Puzzle. Where is Orangetheory opening new locations? Orangetheory told USA TODAY it plans to open 13-17 new studios across the U.S. in 2025, with an emphasis on markets where the company sees continued demand. The company is planning to open locations in the following cities in 2025: Davis, California Visalia, California Hebron, Kentucky Fenway, Massachussets Centerville, Ohio Florence, South Carolina San Antonio, Texas Woodlake, Virginia Where has Orangetheory already opened new locations? Orangetheory has opened seven new studios so far this year, according to the company. Here's where: Fairfield, California West Boynton, Florida Carrolton, Georgia Gainesville, Georgia Grand Rapids, Michigan White Lake, Michigan West Harlem, New York Where are future locations planned for 2026 and beyond? Orangetheory noted it sees growth opportunities in markets including Dallas-Fort Worth, Seattle, Baltimore-Washington, D.C., Boston-Providence and Los Angeles. The company also said it has signed agreements for three new studios in North Carolina and six in Utah.
Health Line
20 hours ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Yahoo
a day ago
- Yahoo
‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge
The parents of a 19-year-old who dreamed of fame and died after trying the TikTok 'dusting' trend are warning others about its deadly risks. Renna O'Rourke and her boyfriend DoorDashed aerosol keyboard cleaner to her parents' Tempe, Arizona, home without her mother's knowledge, Dana O'Rourke told 12 News. The dusting trend, also known as chroming or huffing, involves inhaling common household cleaners to get high for views online. The sensation causes brief euphoria but can cause instant, fatal damage, often due to heart failure, according to the Cleveland Clinic. After inhaling the keyboard cleaner, Renna went into cardiac arrest, spent a week unconscious in the intensive care unit, and then was declared brain-dead. Renna's parents described their late daughter as 'vivacious and caring and loyal.' Her father, Aaron O'Rourke, told 12 News that Renna loved to sing and lit up every room with her smile and laughter. 'She always said, 'I'm going to be famous, dad. Just you watch. I'm going to be famous,' and unfortunately, this is not under the most optimal of circumstances,' Aaron O'Rourke, told the outlet.. Despite the less-than-ideal circumstances, the O'Rourke family is now working to honor Renna by spreading the word about the dangers of huffing for teens and parents. 'There's no ID required. It's odorless. It's everything kids look for. They can afford it, they can get it, and it doesn't show in mom and dad's drug test,' Dana O'Rourke told AZ Family about access to the trendy chemicals. She added, 'Don't take your kid's word for it. Dig deep. Search their rooms. Don't trust — and that sounds horrible, but it could save their life.' A GoFundMe started to help the O'Rourke family with hospital bills, burial and therapy costs, and to spread awareness about huffing has surpassed its $5,000 goal and sits at over $9,000 at the time of publication.
